Amarin reported $175.14M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026